The Latest Analyst Ratings For Edwards Lifesciences
Portfolio Pulse from Benzinga Insights
Edwards Lifesciences (NYSE:EW) received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for EW has increased to $91.56, up from $83.12, indicating a positive outlook from analysts. Key financial indicators such as revenue growth, net margin, ROE, ROA, and debt management reflect the company's strong market position and financial health. Edwards Lifesciences, a leader in medical devices for structural heart disease, shows solid performance and potential for future growth.
March 26, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences has seen a positive shift in analyst ratings, with an increased average price target of $91.56, reflecting optimism about the company's future performance.
The increase in the average price target to $91.56 from $83.12, along with positive financial indicators such as revenue growth and net margin, suggests analysts are optimistic about EW's future. This optimism is likely to influence investor sentiment positively, potentially leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100